Efruxifermin
AssetAlso EFX, AKR-001, AMG-876
FGF21 analog activating beta-Klotho-dependent FGF receptors to improve insulin sensitivity and lipid metabolism and reduce liver fibrosis.
- Stage
- Phase 3
- Modality
- Protein or enzyme
- Target
- Lipid and ceramide metabolism
- 4
- Indications
- 2
- Trials
- 1
- Developer
Indications
4Mash metabolic dysfunction associated steatohepatitis
Phase 3, Recruiting, NCT06528314, clinicaltrials.gov, 15 Oct 2026
MASH with fibrosis
Phase 3, Recruiting, NCT06215716, clinicaltrials.gov, 7 Oct 2026
NASH - nonalcoholic steatohepatitis
Phase 3, Recruiting, NCT06528314, clinicaltrials.gov, 15 Oct 2026
1 more
In the full profile
- Targets and what it contains5
- Owner and partners1
- Trials2
- Evidence for its targets5
- Competitors11
- Aging relevance1
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.